专题：专题|2024年度A股CFO数据报告：美的集团钟铮年薪946万，比亚迪周亚琳896万 作为上市公司核心管理层关键成员，财务总监CFO的地位与作用至关重要。新浪财经《2024年度A股 CFO数据报告》显示，2024年A股上市公司财务总监CFO群体薪酬规模合计达42.70亿元，平均年薪为 81.48万元。 其中，年薪排行前三的CFO分别为国邦医药的龚裕达、浙江医药的李齐融、新华制药的侯宁，三人年薪 分别为193.09万元、184.18 万元、156.7万元。 从薪酬变动幅度看（仅统计任职两年以上CFO薪资数据），黄山胶囊的刘清科2024年薪酬降幅最大，同 比降幅达19.04%；能特科技的蹇丹薪酬增幅最大，同比涨幅达100.58%。 分行业来看，统计数据显示，剔除2024年时任CFO已离任的公司后，A股共有43家上市原料药公司，其 聘任总体情况如下（部分统计口径剔除无效数据）。 责任编辑：公司观察 从CFO的年龄分布来看，40岁-50岁CFO是市场的中坚力量，占比共计达到36%；60岁以上的CFO占比 为5%；50岁-60岁的CFO群体占比为33%；40岁及以下CFO群体占比为26%。其中，目前仍任职的最年 ...

Core Viewpoint - The company is committed to a global market layout strategy, with its raw material products already being sold in the United States, although their contribution to overall revenue is currently low [1]. Group 1 - The company aims to enhance its competitiveness in the global pharmaceutical supply chain through continuous accumulation in R&D collaboration, lean production, and quality management systems [1]. - The company is steadily advancing its international business expansion [1].

（记者 张明双） 每经AI快讯，有投资者在投资者互动平台提问：董秘你好，请问咱们公司产品卖往美国的多吗？美国 现在要求他们药企巨头全部降低药价，这是不是意味着他们向我们这边性价比高的原料和研发服务有可 能加大比例？ 海森药业（001367.SZ）8月5日在投资者互动平台表示，公司坚持全球化市场布局战略，原料药产品已 有销往美国，但现阶段其对整体营收的贡献程度相对较低。公司将依托自身在研发协同、精益生产及质 量管理体系的持续积累，提升在全球医药产业链中的竞争力，稳步推进业务的国际化拓展。 ...

海森药业今日上涨4.79%，全天换手率31.12%，成交额3.19亿元，振幅8.83%。龙虎榜数据显示，机构净 买入1065.42万元，营业部席位合计净买入1850.98万元。 海森药业8月4日交易公开信息 | 买/卖 | 会员营业部名称 | 买入金额（万元） | 卖出金额（万元） | | --- | --- | --- | --- | | 买一 | 方正证券股份有限公司浙江分公司 | 2662.56 | 13.29 | | 买二 | 机构专用 | 1343.88 | 522.30 | | 买三 | 机构专用 | 812.03 | 364.13 | | 买四 | 机构专用 | 764.25 | 451.70 | | 买五 | 机构专用 | 674.26 | 541.65 | | 卖一 | 机构专用 | 216.53 | 865.75 | | 卖二 | 光大证券股份有限公司广州马场路证券营业部 | 1.05 | 702.50 | | 卖三 | 机构专用 | 674.26 | 541.65 | | 卖四 | 机构专用 | 1343.88 | 522.30 | | 卖五 | 麦高证券有限责任公司北京分公司 | 39 ...

资金流向方面，今日该股主力资金净流出1505.25万元，其中，特大单净流出787.77万元，大单资金净流 出717.48万元。近5日主力资金净流入2900.88万元。（数据宝） 海森药业8月1日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 机构专用 | 864.43 | 196.83 | | 买二 | 麦高证券有限责任公司北京分公司 | 691.82 | 268.60 | | 买三 | 机构专用 | 546.52 | 92.82 | | 买四 | 机构专用 | 544.84 | 114.09 | | 买五 | 机构专用 | 542.11 | 0.00 | | 卖一 | 中信证券股份有限公司浙江分公司 | 139.48 | 1359.94 | | 卖二 | 中信证券股份有限公司福州湖东路证券营业部 | 1.09 | 728.93 | | 卖三 | 国泰海通证券股份有限公司上海长宁区江苏路证券营业 | 15.80 | 443.88 | | | 部 | | | | 卖四 | 东 ...

海森药业今日上涨3.71%，全天换手率35.09%，成交额3.57亿元，振幅10.24%。龙虎榜数据显示，机构净卖出1332.99万元，营业部席位合计净买入2275.09万元。 深交所公开信息显示，当日该股因日换手率达35.09%上榜，机构专用席位净卖出1332.99万元。 证券时报•数据宝统计显示，上榜的前五大买卖营业部合计成交6938.49万元，其中，买入成交额为3940.30万元，卖出成交额为2998.19万元，合计净买入942.10万元。 具体来看，今日上榜的营业部中，共有3家机构专用席位现身，即卖二、卖三、卖四，合计买入金额288.49万元，卖出金额1621.48万元，合计净卖出1332.99万元。 资金流向方面，今日该股主力资金净流入2609.13万元，其中，特大单净流入532.17万元，大单资金净流入2076.96万元。近5日主力资金净流入6135.88万元。（数据宝） 海森药业7月31日交易公开信息 ...

Group 1 - Haisen Pharmaceutical's stock rose by 3.71% with a turnover rate of 35.09% and a trading volume of 357 million yuan, showing a volatility of 10.24% [2] - Institutional investors net sold 13.33 million yuan, while brokerage seats collectively net bought 22.75 million yuan [2] - The stock was listed on the Shenzhen Stock Exchange due to its high turnover rate, with institutional proprietary seats net selling 13.33 million yuan [2] Group 2 - The top five brokerage seats accounted for a total transaction volume of 69.38 million yuan, with a buying amount of 39.40 million yuan and a selling amount of 29.98 million yuan, resulting in a net buying of 9.42 million yuan [2] - Among the brokerage seats, three institutional proprietary seats were involved, with a total buying amount of 2.88 million yuan and a selling amount of 16.21 million yuan, leading to a net sell of 13.33 million yuan [2] - The stock experienced a net inflow of 26.09 million yuan from main funds today, including a net inflow of 5.32 million yuan from large orders and 20.77 million yuan from major funds, with a total net inflow of 61.36 million yuan over the past five days [2]

Summary of Key Points Core Viewpoint - The announcement details the completion of a share reduction plan by the company's general manager, Mr. Ai Lin, who has reduced his holdings in the company by 1,472,113 shares, representing 0.9690% of the total share capital [1][2]. Group 1: Share Reduction Details - Mr. Ai Lin executed the share reduction through centralized bidding, with an average reduction price of 21.7325 CNY per share [1]. - The total number of shares reduced was 1,472,113, with a price range between 21.3500 CNY and 22.2000 CNY per share [1][2]. - Prior to the reduction, Mr. Ai Lin held 6,014,252 shares, which accounted for 3.9587% of the total share capital [2]. Group 2: Post-Reduction Holdings - After the reduction, Mr. Ai Lin's remaining shares total 4,542,139, which is 2.9897% of the total share capital [2]. - The shares reduced were from the unrestricted category, leaving Mr. Ai Lin with only restricted shares [2]. Group 3: Compliance and Commitments - The share reduction plan was in compliance with relevant laws and regulations, including the Securities Law of the People's Republic of China [2][3]. - Mr. Ai Lin has adhered to his commitments regarding share transfers, including a lock-up period and conditions for future reductions [3][4]. - The reduction will not affect the company's control structure or governance [5].

证券代码：001367 证券简称：海森药业 公告编号：2025-030 浙江海森药业股份有限公司 关于公司董事、高级管理人员减持计划实施完成的公告 本公司董事、总经理艾林先生保证向本公司提供的信息内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 份（包含前述股份因资本公积金转增股本增加的股份）； 注 2：本次减持价格区间为 21.3500 元/股—22.2000 元/股。 （二）股东本次减持前后持股情况 | 股东 | | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | 名称 | 股份性质 | 股数 | 占总股本 | 股数 | 占总股本 | | | | （股） | 比例（%） | （股） | 比例（%） | | 艾林 | 合计持有股份 | 6,014,252 | 3.9587 | 4,542,139 | 2.9897 | | | 其中：无限售条件股份 | 1,472,113 | 0.9690 | 0 | 0 | | | 有限售条件股份 | 4, ...

Group 1: Industry Development Direction - The company will enhance R&D innovation and improve product quality and production processes to solidify its market position in the raw material drug sector [1] - There will be increased investment in the R&D, production, and sales of chemical drug formulations, gradually extending into the formulation industry chain [1] - This extension aims to better meet customer needs, increase product added value, and enhance market competitiveness for sustainable development [1] Group 2: Market Value Management - The company emphasizes market value management through a series of measures, focusing on core business development and enhancing operational efficiency to drive value growth [2] - Active communication with investors is maintained through performance briefings and interactive platforms to enhance information transparency [2] - A reasonable and sustainable profit distribution plan is in place to create a long-term, stable shareholder value return mechanism [2] Group 3: Product Development Focus - Currently, the company has 17 products under research, covering areas such as antiviral, antidepressant, and lipid-lowering treatments [2] - Key development directions for the year include improving existing product processes to reduce production costs and enhance market competitiveness [2] - Accelerating the transition of existing raw material products to formulations and ensuring smooth commercialization of research products are prioritized to create new business growth points and profit sources [2]